-
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
yahoo.com
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced additional details for the company’s planned global, multi-center
Open original → -
Absci (NASDAQ:ABSI) Stock Price Down 8.3% - What's Next?
marketbeat.com
Absci (NASDAQ:ABSI) Stock Price Down 8.3% - Time to Sell?
Open original → -
Research Analysts’ Updated EPS Estimates for September 23rd (AAPL, ABSI, ADUR, ALV, AURR, BLSH, BOKU, BP, CCP, CGNX)
tickerreport.com
Research Analysts’ updated eps estimates for Wednesday, September 23rd: Apple (NASDAQ:AAPL) had its buy rating reissued by analysts at Bank of America Corporation. They currently have a $370.00 target price on the stock. Absci (NASDAQ:ABSI) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $11.00 target price […]
Open original → -
Absci (NASDAQ:ABSI) Earns "Buy" Rating from Needham & Company LLC
Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price target on shares of Absci in a research report on Wednesday.
Open original → -
Novo eyes hair-loss market as Ozempic maker looks to diversify | $NVO $NONOF $LLY $ABSI $MANE
seekingalpha.com
No description provided for this story.
Open original → -
Absci (ABSI) Stock Looks Expensive Against Its Book Value
Absci has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$9.82 level is supported by the company’s book value. For anyone looking at the stock today, the key issue is how that accounting base stacks up against the recent share price performance. Over the past 3 years, Absci has delivered a very large share price gain, which raises the question of how much of that move is mirrored in the company’s underlying net assets. The business model...
Open original → -
Financial Contrast: Valneva (NASDAQ:VALN) and Absci (NASDAQ:ABSI)
Absci (NASDAQ:ABSI – Get Free Report) and Valneva (NASDAQ:VALN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings. Profitability This table compares Absci and Valneva’s net margins, […]
Open original → -
Absci (NASDAQ:ABSI) Stock Price Up 12.5% - Here's What Happened
Absci (NASDAQ:ABSI) Trading Up 12.5% - Time to Buy?
Open original → -
Artificial Intelligence Stocks Worth Watching - September 17th
Tempus AI, Hut 8, Fluence Energy, SentinelOne, Absci, SoundHound AI, and Webus International are the seven Artificial Intelligence stocks to watch today, according to MarketBeat's stock screener tool. Artificial intelligence stocks are shares of companies involved in developing, providing, or using
Open original → -
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript | $ABSI
No description provided for this story.
Open original → -
Squarepoint Ops LLC Sells 228,841 Shares of Absci Corporation $ABSI
Squarepoint Ops LLC reduced its stake in Absci Corporation (NASDAQ:ABSI - Free Report) by 58.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 162,449 shares of the company's stock after selling 228,84
Open original → -
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
insidermonkey.com
Bloomberg reported on August 29 that hair-loss drug stocks are surging as Wall Street bets on a new pharmaceutical goldmine following the GLP-1 weight-loss boom. Shares of Veradermics, Incorporated (NYSE:MANE) have climbed nearly 500% since its February 2026 initial public offering, while Absci Corporation (NASDAQ:ABSI)’s stock has more than doubled so far in 2026. Switzerland’s […] Bloomberg reported on August 29 that hair-loss drug stocks are surging as Wall Street bets on a new pharmaceutical goldmine following the GLP-1 weight-loss boom. Shares of Veradermics, Incorporated (NYSE:MANE) have climbed nearly 500% since its February 2026 initial public offering, while Absci Corporation (NASDAQ:ABSI)’s stock has more than doubled so far in 2026. Switzerland’s Cosmo NV also posted positive trial results for an experimental male hair-loss treatment, though its shares have lagged the U.S. competitors. Pattern hair loss affects an estimated 50 million men and 30 million women in the U.S., and no new hair-loss drug has won FDA approval since the late 1990s. It leaves patients with only older options like topical minoxidil and prescription finasteride, both of which carry side effects including heart palpitations and lowered sex drive. Veradermics reported positive results in April for an oral minoxidil tablet in men and followed with promising mid-stage data for women with thinning hair in July, potentially positioning it as the first approved pill for female-pattern hair loss. Jefferies analyst Roger Song holds the Street’s highest price target on the stock. Copyright: wasansos1 / 123RF Stock Photo Bull Case The addressable market is large and genuinely underserved. Roughly 80 million Americans experience pattern hair loss, yet no new drug has reached the market in nearly three decades. That gap leaves substantial unmet demand in a category that Wall Street has largely ignored. Veradermics, Incorporated (NYSE:MANE) has cleared two important clinical hurdles this year. Positive results in men in April followed promising mid-stage data in women in July, reducing some of the clinical risk that typically accompanies an early-stage biotech. The results could also position Veradermics to become the first company to win approval for an oral treatment for female-pattern hair loss, since no approved pills currently target that condition. Analysts see room for multiple winners in the hair-loss market. Jefferies argues that patients often combine treatments, which could allow several approved drugs to generate meaningful sales. That dynamic could create a large market for multiple companies rather than forcing investors to identify a single winner. Existing treatments also leave room for improvement. Minoxidil and finasteride have struggled with tolerability and limited adoption, giving a more effective and better-tolerated oral treatment an opportunity to take share from established options rather than compete as another me-too product. Absci Corporation (NASDAQ:ABSI) gives investors another potential way to benefit from the growing hair-loss drug market. The firm is developing an AI-designed injectable treatment. It gives it a differentiated approach as drugmakers pursue alternatives to traditional hair-loss therapies. A large commercial opportunity in the category, which could give Absci significant upside if its treatment gains traction and competes effectively. Bear Case Veradermics, Incorporated (NYSE:MANE)’s stock rally has outpaced its clinical evidence. The company remains in early- and mid-stage development without FDA approval, while its shares have gained nearly 500% since its February IPO. That valuation already reflects substantial expectations for success, leaving the stock vulnerable to disappointment if pivotal trials produce weaker results. The commercial model lacks the safety net that GLP-1 drugs received from established medical demand. Hair loss does not qualify as a medical necessity, so patients would likely pay out of pocket for an approved treatment. That structure could limit adoption and make consumers more sensitive to price than patients who receive insurance coverage for medically necessary treatments. Veradermics also faces competition from other drug developers. Absci Corporation (NASDAQ:ABSI) is developing an AI-designed injectable treatment, while Cosmo NV plans to seek regulatory approval for its topical treatment in early 2027. Jefferies estimates a $3 billion sales opportunity for Cosmo’s drug alone, giving Veradermics another competitor as it tries to establish its position. The comparison with GLP-1 drugs sets an exceptionally high bar. Calling hair loss “the next Ozempic” and comparing the opportunity with the trillion-dollar valuations of Eli Lilly and Novo Nordisk could create unrealistic expectations. Hair loss represents a more price-sensitive market than obesity treatment because patients generally pay out of pocket, which could limit the category’s ability to replicate the scale of the GLP-1 boom. Absci Corporation (NASDAQ:ABSI) faces competition as it tries to establish its position in the hair-loss market. Veradermics has already produced positive clinical data, while Cosmo NV plans to seek regulatory approval for its topical treatment in early 2027. Absci needs its AI-designed injectable to demonstrate clear advantages in effectiveness and tolerability to win patients as competitors enter the market. Hedge Fund Data Insider Monkey’s database shows Veradermics, Incorporated (NYSE:MANE) was held by 37 hedge funds in the second quarter of 2026, up from 30 in the first quarter. Absci Corporation (NASDAQ:ABSI)’s fund count rose to 39 from 23. Both stocks are drawing rapidly increasing hedge fund attention. Conclusion The growing hair-loss market gives Veradermics and Absci a significant opportunity to develop new treatments for a large underserved patient base. However, clinical uncertainty, out-of-pocket costs, and high competition could keep the market from matching the scale of the GLP-1 boom. Investors should watch whether these companies can turn promising treatments into commercially successful products. [im-yf-promo] While we acknowledge the potential of MANE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. [/im-yf-promo] Should you invest in MANE now? While we acknowledge the risk and potential of MANE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MANE and that has massive upside potential, check out our report about this cheapest AI stock. See Our Top Pick →Insider Monkey Premium Services READ NEXT: Meta’s $18 Billion Teen Safety Deal Puts the Pressure on TikTok and YouTube Next and Tesla (TSLA) Rolls Out its Safety Numbers ahead of a Make-or-Break EU Vote. Disclosure: None. Follow Insider Monkey on Google News. Subscribe to Insider Monkey's Free Daily Newsletter and Join 100K+ Readers or Subscribe with Google We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Open original → -
Lifesci Capital Begins Coverage on Absci (NASDAQ:ABSI)
Lifesci Capital assumed coverage on shares of Absci in a research note on Wednesday. They issued an "outperform" rating on the stock.
Open original → -
Absci's Billion-Dollar Hair Bet: Why The AI Story Doesn't Add Up | $ABSI $MRK $AZN $LBTSF $LLY
No description provided for this story.
Open original → -
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Brokerages
Absci Corporation (NASDAQ:ABSI - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and eight have given a buy rating to t
Open original → -
Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade) | $LLY $ABSI
No description provided for this story.
Open original → -
Absci (NASDAQ:ABSI) Price Target Raised to $16.00
BTIG Research raised their price target on Absci from $13.00 to $16.00 and gave the company a "buy" rating in a research note on Tuesday.
Open original → -
Absci Corporation $ABSI Shares Bought by Bank of America Corp DE
Bank of America Corp DE raised its holdings in Absci Corporation (NASDAQ:ABSI - Free Report) by 55.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 487,193 shares of the company's stock after acquiring an additional 173,361 shares during the period. Bank o
Open original → -
Absci (NASDAQ:ABSI) Stock Price Down 4.8% - Should You Sell?
Absci (NASDAQ:ABSI) Shares Down 4.8% - Time to Sell?
Open original → -
From his parents’ basement to your medicine cabinet: Absci CEO endeavors to create biotech’s Apple
fiercebiotech.com
The overwhelming demand for GLP-1 weight loss drugs has reshaped the drug market, empowering consumers to take charge of their own health and removing barriers between their wallets and their medicine cabinets.
Open original → -
Absci Corp: Form 4 - Statement of changes in beneficial ownership of securities
sec.gov
No description provided for this story.
Open original → -
Absci to Participate in Upcoming Investor Conferences
globenewswire.com
VANCOUVER, Wash. and NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences:
Open original → -
Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade
beincrypto.com
Hair loss biotechs Veradermics, Absci, and Cosmo are drawing investor bets on a market untouched since the 1990s.
Open original → -
Artia Global Partners LP Acquires Shares of 464,444 Absci Corporation $ABSI
Artia Global Partners LP acquired a new position in shares of Absci Corporation (NASDAQ:ABSI - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 464,444 shares of the company's stock, valued at approximately $5,383,000. Absci accounts for ab
Open original → -
Absci (NASDAQ:ABSI) Trading 8.5% Higher - What's Next?
Absci (NASDAQ:ABSI) Trading 8.5% Higher - Still a Buy?
Open original → -
Absci (NASDAQ:ABSI) Shares Down 7.8% - Should You Sell?
Absci (NASDAQ:ABSI) Shares Down 7.8% - Here's Why
Open original → -
Absci (NASDAQ:ABSI) Shares Gap Up - Should You Buy?
Absci (NASDAQ:ABSI) Shares Gap Up - Time to Buy?
Open original → -
Absci (ABSI) Q2 2026 Earnings Call Transcript
fool.com
Biotech extends runway to 2028 with $100M financing and Eli Lilly deal. Image source: The Motley Fool. DATETuesday, Aug. 11, 2026 at 4:30 p.m. ETCALL PARTICIPANTSCorporate Vice President and Investor Relations-Alexander KhanFounder and Chief Executive Officer-Sean McClainChief Financial Officer and Chief Business Officer-Zachariah JonassonChief Medical Officer, Head of R&D-Ransi SomaratneNeed a quote from a Motley Fool analyst? Email pr@fool.comTAKEAWAYSRevenue -- $0.3 million for the quarter ended June 30, 2026, compared to $0.6 million for the same period in 2025, reflecting fluctuations in partner program milestones.Research and Development Expenses -- $22.6 million, an increase from $20.5 million in the prior year period primarily driven by the advancement of the ABS-201 clinical program.Selling, General, and Administrative Expenses -- $9.2 million, representing an increase from $8.5 million due to higher stock-based compensation and administrative costs.Net Loss -- $33.2 million, or $0.21 per share, compared to a net loss of $30.6 million, or $0.24 per share, in the second quarter of 2025.Cash and Marketable Securities -- $201.1 million as of June 30, 2026, which is an increase from $125.7 million as of March 31, 2026.Financing Proceeds -- $93.6 million in net proceeds from an underwritten common stock offering and a strategic investment from Eli Lilly completed in June 2026.Eli Lilly Strategic Investment -- $40 million as part of a collaboration focused on the clinical development strategy for ABS-201 in endometriosis.Operating Cash Runway -- Sufficient to fund the company's operating plan into the second half of 2028, supported by the recent $100 million financing.ABS-201 Estimated Half-life -- At least 65 days based on interim pharmacokinetic data from single ascending dose cohorts, suggesting potential for infrequent dosing.Target Dosing Interval -- 2 to 3 doses over a 6-month period, which is intended to maintain receptor occupancy levels necessary for hair regeneration.Target Receptor Occupancy -- Greater than 90%, which management identified as the threshold required to maintain the hair follicle in a prolonged anagen state.Pattern Hair Loss Market Opportunity -- $25 billion total available market in the United States, based on consumer research and feedback from key opinion leaders.Endometriosis Peak Sales Potential -- Greater than $4 billion for a disease-modifying therapy targeting a population of approximately 9 million women in the U.S.Atlas Discovery Engine Efficiency -- 1,000-fold reduction in library size required for lead identification through agentic AI model improvements.Platform Performance Metrics -- Under 2.5 years and less than $15 million in total cost to advance internal programs from discovery to IND-enabling studies.Target Hair Growth Efficacy -- 30 to 35 hairs per square centimeter at 26 weeks, a target management believes would represent a top-tier product profile.U.S. Pattern Hair Loss Population -- 80 million people, including 30 million women, identified as the addressable patient base for ABS-201.Phase II Endometriosis Timeline -- Initiation anticipated in the fourth quarter of 2026, with proof-of-concept data expected in the second half of 2027.Pattern Hair Loss Data Readouts -- Interim 13-week proof-of-concept data expected in late 2026 and full 26-week data expected in early 2027.ABS-202 Development Status -- Preclinical anti-prolactin receptor antibody currently being evaluated for an undisclosed immunology and inflammation indication.Formulation Improvements -- AI-designed candidates are now optimized for high concentration formulation development to reduce IND-enabling timelines.Patient Enrollment -- Multiple ascending dose portion of the HEADLINE trial is currently enrolling according to the original project plan.Depreciation and Amortization -- $2.7 million for the second quarter, compared to $3.0 million for the second quarter of 2025.SUMMARYManagement at Absci Corp. (NASDAQ:ABSI) reported progress in transitioning from a pure discovery platform to a clinical-stage developer of proprietary therapeutics. The company emphasized its focus on the prolactin receptor franchise, specifically the ABS-201 program for pattern hair loss and endometriosis. The strategic narrative centered on the deployment of Atlas, a new agentic discovery engine designed to accelerate the target-to-lead process. A $100 million financing round, including $40 million from Eli Lilly, extended the company's cash runway into 2028. Full Conference Call TranscriptOperator: Good day, and thank you for standing by. Welcome to the Absci second quarter business update. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Alexander Khan, Corporate Vice President and Investor Relations Please go ahead.Alexander Khan: Thank you. Earlier today, Absci released financial and operating results for the quarter ended 06/30/2026. If you have not received this news release or if you would like to be added to the company's distribution list, please send an email to investors@Absci.com. An archived webcast of this call will be available for replay on Abzai's Investor Relations website at investors.absci.com for at least 90 days after this call. Joining me today are Sean McClain, Absci's founder and CEO Zachariah Jonasson, Chief Financial Officer and Chief Business Officer and Ransi Somaratne, chief medical officer, head of R&D.Before we begin, I would like to remind you that management will make statements during this call that are forward looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. You should not place undue reliance on forward looking statements. These include statements regarding the development and clinical progress of our pipeline programs including ABS-201, the design, enrollment conduct, and timelines of our ongoing Phase IIa headline trial of ABS-201.The anticipated timing of an interim proof of concept data readout for ABS-201 in the second 26 and full proof of concept data in early 27 the potential events in a BABS-201 into Phase III development, the anticipated initiation of a Phase II clinical trial of ABS-201 for endometriosis fourth quarter 26 and potential proof of concept readout in second half of 27 Anticipated characteristics and product profile of ABS-201 as the drug product. Our target product profile attributes, the potential for an expedited development pathway, including the possibility of advancing directly from Phase IIa to Phase III.A plan to engage with the FDA regarding development strategy Our partnership with Eli Lilly including anticipated benefits thereof in Eli Lilly's participation on our endometriosis advisory board The capabilities anticipated benefits of our platform technology such as Atlas, and potential market opportunity and commercial prospects for ABS-201. Certain statements may also include projections regarding potential market opportunity. These estimates are based on various assumptions, including potential regulatory approval, final approved label, and the evolving competitive landscape, any of which could cause our actual addressable market to differ materially from these projections. In addition, certain research findings discussed today reflect participant responses to a hypothetical product profile and do not represent clinical results of ABS-201.Additional information regarding the risks and uncertainties that could affect our forward looking statements is set forth in the press release Absci issued today. Our most recent annual report on Form 10-K, subsequent documents and reports filed by Absci from time to time with the SEC. Except as required by law, Absci disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward looking statements either because of new information, future events or otherwise. This conference call contains time sensitive information that is accurate only as of the live broadcast August 11, 2026. With that, I will turn the call over to Sean.Sean McClain: Thanks, Alex. Good afternoon, everyone. Thanks for joining us today. Absci continues to execute. I will walk you through recent highlights. Including key progress on ongoing headline trial, our new partnership with Eli Lilly, and our $100 million financing completed at the end of June. Starting with headline. In June, we released positive interim Phase I data. The data suggests the study drug was well tolerated with favorable safety and tolerability. And based on interim PK data, ABS-201's half life supports the potential for just 2 to 3 injections over 6 months. This is exactly why we built our AI platform. To design molecules that meet our target product profile that we set out from day 1.You have heard us say the prolactin mechanism is underappreciated. Everything we have learned has only strengthened that conviction, and we believe targeting the prolactin receptor has the potential across numerous diseases. And we are also excited to have a partner who shares in that vision. As you saw in June, we announced that Eli Lilly made a $40 million strategic investment in Absci. Our partnership with Eli Lilly is tailored around the clinical development strategy for ABS-201. And as a part of this collaboration, we are happy to be welcoming a representative from Lilly onto our endometriosis advisory board. Zachariah will provide more details of this partn
Open original → -
Absci (ABSI) Q2 2026 Earnings Call Transcript
Biotech extends runway to 2028 with $100M financing and Eli Lilly deal. Image source: The Motley Fool.Tuesday, Aug. 11, 2026 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading
Open original → -
Function-Focused AI and Integrated Labs Set Absci Apart in Next-Gen Drug Discovery
Absci Corporation is emerging as a clear example of the next phase of AI drug discovery, leveraging AI models centered around molecular function and structure, not genetic sequence alone. Its partnerships, wet-lab integration, and early data have drawn both capital and industry attention, highlighting how this model is redefining the sector’s landscape.
Open original → -
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.
Open original → -
Absci Corp (ABSI) (Q2 2026) Earnings Call Highlights: Strong Cash Position and Promising ...
gurufocus.com
Absci Corp (ABSI) reports positive interim Phase I data for ABS-201, secures $40 million Eli Lilly investment, and extends cash runway into 2028.Related Stocks: ABSI,
Open original → -
Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation
Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci’s recent early Phase 1 ABS-201 update and Eli Lilly’s US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareholder...
Open original → -
Absci Corp: Form 4 - Statement of changes in beneficial ownership of securities
No description provided for this story.
Open original → -
Absci Corp: Form 3 - Initial statement of beneficial ownership of securities
No description provided for this story.
Open original → -
Recursion Pharmaceuticals Q2 Earnings Call Highlights
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming expectations for an operating runway through early 2028. The
Open original → -
Absci (ABSI) to Announce Earnings on Tuesday
Absci (NASDAQ:ABSI) will be releasing its Q2 2026 earnings after the market closes on Tuesday, August 11. (View Earnings Report at
Open original → -
Absci Corporation (NASDAQ:ABSI) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Absci Corporation (NASDAQ:ABSI - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and eight have assigned a bu
Open original → -
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) t
Open original → -
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in ABSCI CORP (ABSI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Open original → -
Absci (NASDAQ:ABSI) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised shares of Absci from a "sell" rating to a "hold" rating in a research report on Saturday.
Open original → -
Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity Raise - Has The Bull Case Changed?
Earlier this week, Absci Corporation reported encouraging interim Phase 1 data from its HEADLINE trial of ABS-201 for androgenetic alopecia, showing favorable safety, an estimated half-life of at least 65 days, and progression into a multiple ascending dose stage. On the heels of these results, Absci also completed a roughly US$100.00 million follow-on equity offering backed by Eli Lilly & Company and other institutional investors, underscoring external confidence in the ABS-201 program...
Open original → -
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Absci Corporation (NASDAQ:ABSI - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and eight have assi
Open original → -
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Open original → -
Absci Corp: Form 424B5 - Prospectus [Rule 424(b)(5)]
No description provided for this story.
Open original → -
STAT+: Eli Lilly dives into hair loss treatments with investment in AI startup Absci
statnews.com
Eli Lilly is investing in a small startup developing a medication to spur hair growth, and potentially also treat endometriosis. The pharmaceutical giants behind the monumentally successful weight loss drugs Wegovy and Mounjaro have been teasing an expansion into other aesthetic fields like hair loss or skin care. Now, one of them is making a move, investing in a small startup developing a medication to spur hair growth, and potentially also treat endometriosis. On Wednesday, Absci announced that it raised $100 million from a group led by Eli Lilly. Lilly brought the lion’s share of the funding, handing over $40 million in exchange for equity in Absci, which is publicly traded on the Nasdaq. Continue to STAT+ to read the full story…
Open original → -
Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain | $LLY $RLAY $ABSI
No description provided for this story.
Open original → -
Stock Movers: Wendy's, Hertz, Absci (Podcast)
bloomberg.com
Source: Bloomberg, 0:00 Hertz Global Holdings Inc Photographer: David Paul Morris/Bloomberg
Open original → -
Absci prices $100 m underwritten common at $7.41 per share to fund advancement of ABS-201
awesomecapital.blogspot.com
Absci prices $100 million underwritten common stock offering at $7.41 per share to fund advancement of ABS-201Eli Lilly and leading institutional investors are participating in the underwritten common stock offering.Proceeds will also be used for general corporate purposes.Absci reports positive interim Phase 1 data from HEADLINE trial of ABS-201.
Open original → -
Analysts’ Price Target Changes for June 24th (AAL, ABSI, ATD, BB, BLDP, BSX, CELH, CNR, CP, DAL)
Analysts’ price target changes for Wednesday, June 24th: American Airlines Group (NASDAQ:AAL) had its price target increased by Jefferies Financial Group Inc. from $15.00 to $16.00. They currently have a hold rating on the stock. Absci (NASDAQ:ABSI) had its price target raised by BTIG Research from $9.00 to $13.00. BTIG Research currently has a buy […]
Open original →